Total submissions: 15
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Biesecker Lab/Clinical Genomics Section, |
RCV000079305 | SCV000050757 | likely benign | not provided | 2013-06-24 | criteria provided, single submitter | research | |
Eurofins Ntd Llc |
RCV000223757 | SCV000111175 | benign | not specified | 2016-06-21 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001085859 | SCV000285600 | benign | Long QT syndrome | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000241853 | SCV000319009 | benign | Cardiovascular phenotype | 2016-06-27 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Gene |
RCV000223757 | SCV000512465 | benign | not specified | 2016-10-10 | criteria provided, single submitter | clinical testing | This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV000079305 | SCV000697556 | likely benign | not provided | 2016-01-25 | criteria provided, single submitter | clinical testing | Variant summary: CACNA1C c.5918G>A affects a conserved nucleotide, resulting in amino acid change from Arg to Gln. 3/4 in-silico tools predict this variant to be benign. This variant is found in 433/121010 control chromosomes including the large and broad populations from ExAC at a frequency of 0.0035782, which is about 358 times greater than the maximal expected frequency of a pathogenic allele (0.00001) in this gene, suggesting this variant is benign. Five homozygotes were reported in ExAC. This variant has been reported in multiple LQTS and BrS patients without strong evidence for causality (eg. co-segregation studies). Clinical diagnostic labs have classified this variant as a VUS or likely benign before the large and diverse ExAC control cohorts were available. Taken together, this variant was classified as likely benign. |
Ce |
RCV000079305 | SCV004033181 | benign | not provided | 2024-04-01 | criteria provided, single submitter | clinical testing | CACNA1C: PM5, BP4, BS1, BS2 |
Breakthrough Genomics, |
RCV000079305 | SCV005213588 | likely benign | not provided | criteria provided, single submitter | not provided | ||
Blueprint Genetics | RCV000157127 | SCV000206850 | likely benign | Short QT syndrome | 2014-10-14 | no assertion criteria provided | clinical testing | |
Stanford Center for Inherited Cardiovascular Disease, |
RCV000223757 | SCV000280058 | uncertain significance | not specified | 2014-12-02 | no assertion criteria provided | clinical testing | Note this variant was found in clinical genetic testing performed by one or more labs who may also submit to ClinVar. Thus any internal case data may overlap with the internal case data of other labs. The interpretation reviewed below is that of the Stanford Center for Inherited Cardiovascular Disease. Based on the data reviewed we consider this a variant of uncertain significance. This variant is novel. Pathogenic variants in CACNA1C are associated with Timothy syndrome and Brugada syndrome. This is a semi-conservative amino acid change with a hydrophilic basic polar Arginine replaced with a hydrophilic polar Glutamine. The variant is found in a highly conserved region of the CACNA1C gene. The reporting lab observed the variant in 2 out of 353 presumably healthy individuals of mixed ethnic background. Based on these data it is currently unclear whether this variant can cause disease, however given the presence in controls for a variant in a gene thus far only associated with quite rare diseases, it seems most likely that this variant does not cause rare Mendelian disease such as long QT syndrome. |
Clinical Genetics, |
RCV000079305 | SCV001918606 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000079305 | SCV001930008 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000079305 | SCV001958595 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000079305 | SCV001972918 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Prevention |
RCV003925045 | SCV004745998 | benign | CACNA1C-related disorder | 2019-09-17 | no assertion criteria provided | clinical testing | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |